N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study
出版年份 2020 全文链接
标题
N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 2, Pages 511
出版商
MDPI AG
发表日期
2020-01-15
DOI
10.3390/ijms21020511
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Aberrant N-cadherin expression in cancer
- (2019) Zhan-Qi Cao et al. BIOMEDICINE & PHARMACOTHERAPY
- Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis
- (2018) Yong Luo et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
- (2018) Shinichiro Kashiwagi et al. Journal of Translational Medicine
- Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
- (2018) Takaaki Oba et al. Oncotarget
- Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer
- (2018) TAKAAKI MASUDA et al. ANTICANCER RESEARCH
- Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
- (2018) Javier Cortes et al. CANCER TREATMENT REVIEWS
- Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy
- (2018) José Marrugo-Ramírez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
- (2018) Ryutaro Mori et al. World Journal of Surgical Oncology
- Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC)
- (2018) HIROAKI WAKIYAMA et al. ANTICANCER RESEARCH
- N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
- (2018) Krzysztof Marek Mrozik et al. BMC CANCER
- Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
- (2017) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Liquid biopsy: a step forward towards precision medicine in urologic malignancies
- (2017) Ashley Di Meo et al. Molecular Cancer
- Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer
- (2017) Sho Nambara et al. Oncotarget
- Circulating exosomal microRNA-203 is associated with metastasis possibly via inducing tumor-associated macrophages in colorectal cancer
- (2017) Yuki Takano et al. Oncotarget
- Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
- (2016) X. Pivot et al. ANNALS OF ONCOLOGY
- Cadherins: The Superfamily Critically Involved in Breast Cancer
- (2016) Maeirah Afzal Ashaie et al. CURRENT PHARMACEUTICAL DESIGN
- N-Cadherin and Fibroblast Growth Factor Receptors crosstalk in the control of developmental and cancer cell migrations
- (2016) Thao Nguyen et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
- (2016) Tsutomu Takashima et al. LANCET ONCOLOGY
- Clinical and biological significance of circulating tumor cells in cancer
- (2016) Takaaki Masuda et al. Molecular Oncology
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer
- (2015) H Ueo et al. BRITISH JOURNAL OF CANCER
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2015) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
- (2014) T Yoshida et al. BRITISH JOURNAL OF CANCER
- The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
- (2014) Saskia Litière et al. EUROPEAN JOURNAL OF CANCER
- Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
- (2014) Masato Terashima et al. SpringerPlus
- Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma
- (2013) Kate Vandyke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis
- (2013) T. Yokobori et al. CANCER RESEARCH
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating–cancer stem cells: distinct, overlapping or same populations
- (2011) S Floor et al. ONCOGENE
- PrognoScan: a new database for meta-analysis of the prognostic value of genes
- (2009) Hideaki Mizuno et al. BMC Medical Genomics
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now